Search
teniposide (Vumon)
Tradename: Vumon.
Indications:
- treatment of refractory childhood, acute lymphocytic leukemia (ALL) in combination with other antineoplastic agents
- non-Hodgkin's lymphoma
- neuroblastoma [3]
Dosage:
Injection:
- formulated in polyethoxlated castor oil & dehydrated alcohol (43%): 10 mg/mL (5 mL)
Solution:
- solutions containing 0.5-2 mg/mL remain stable for 4 hours & those containing 0.1-0.2 mg/mL remain stable for 6 hours
Adverse effects:
1) common (> 10%)
- myelosuppression, leukopenia, neutropenia, thrombocytopenia, mucositis, nausea/vomiting, diarrhea, infection
2) less common (1-10%)
- alopecia, rash, hypotension, hypersensitivity, fever, hemorrhage
3) uncommon (< 1%)
- hepatic dysfunction, peripheral neurotoxicity, renal dysfunction, metabolic abnormalities
Drug interactions:
1) plasma clearance of methotrexate may be slightly increased
2) salicylate, sulfamethoxazole & tolbutamide displace teniposide from protein binding sites to a small, but significant extent
Laboratory: test interactions: increases serum K+
Mechanism of action:
1) mitotic inhibitor
2) topoisomerase inhibitor [2]
Related
acute lymphoblastic leukemia (ALL)
General
antimitotic agent; mitotic inhibitor (antineoplastic agent)
epipodophyllotoxin
Properties
INHIBITS: topoisomerase
MISC-INFO: pregnancy-category D
Database Correlations
PUBCHEM correlations
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Harrison's Principles of Internal Medicine, 14th ed.
Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 529
- Deprecated Reference
- Department of Veterans Affairs, VA National Formulary